Table 4.
Comparison of treatment planning dosimetry goals for the target volume: CTV and PTV and OAR planning constraints used for the SBRT-SIB plans, evaluated by DIL location (near the bladder, near the rectum, and near both the bladder and rectum).
| Structure | Parameter | SBRT-SIB plan (mean+SD) // evalution by the DIL localisation | Overall | Multiple comparsions | ||||
|---|---|---|---|---|---|---|---|---|
| nBvs.nR | nBvs.nBR | nRvs.nBR | ||||||
| SIB_nB | SIB_nR | SIB_nBR | p-value | p-value < 0.05 | ||||
| CTV(boost) | V95% | 100.00 ± 0.02 | 99.82 ± 0.56 | 99.84 ± 0.39 | 0.31 | 0.336 | 0.438 | 0.981 |
| PTV(boost) | V95% | 95.26 ± 0.57 | 95.05 ± 0.16 | 95.14 ± 0.41 | 0.27 | 0.241 | 0.622 | 0.764 |
| CTV(Prostate) | V98% | 98.68 ± 1.88 | 99.07 ± 1.32 | 99.17 ± 1.16 | 0.613 | 0.687 | 0.549 | 0.973 |
| PTV(Prostate) | V95% | 96.51 ± 1.36 | 97.41 ± 0.93 | 96.88 ± 1.24 | 0.065 | 0.053 | 0.589 | 0.347 |
| Dmax | 105.39 ± 1.45 | 105.96 ± 1.23 | 106.78 ± 1.60 | 0.44 | 0.421 | 0.666 | 0.915 | |
| CI | 1.16 ± 0.03 | 1.16 ± 0.04 | 1.16 ± 0.04 | 0.941 | 0.937 | 0.992 | 0.972 | |
| HI | 1.31 ± 0.18 | 1.31 ± 0.11 | 1.32 ± 0.11 | 0.978 | 0.999 | 0.981 | 0.983 | |
| GI | 3.21 ± 0.05 | 3.17 ± 0.03 | 3.21 ± 0.05 | < 0.01 | 0.002 | 0.976 | 0.003 | |
| PTV(Prostate) – PTV(boost) | V95% | 96.37 ± 1.40 | 97.30 ± 0.97 | 96.74 ± 1.30 | 0.067 | 0.055 | 0.63 | 0.325 |
| Rectum | V 36Gy < 1cc | 0.32 ± 0.08 | 0.44 ± 0.12 | 0.39 ± 0.09 | < 0.01 | < 0.01 | 0.05 | 0.24 |
| V 36.25Gy < 5% | 0.77 ± 0.21 | 1.09 ± 0.30 | 0.96 ± 0.20 | < 0.01 | < 0.01 | 0.042 | 0.164 | |
| V 32.60Gy < 10% | 2.60 ± 0.26 | 2.95 ± 0.68 | 2.79 ± 0.58 | 0.131 | 0.11 | 0.489 | 0.643 | |
| V 29Gy < 20% | 5.61 ± 0.40 | 5.93 ± 0.98 | 5.90 ± 0.80 | 0.36 | 0.398 | 0.468 | 0.992 | |
| V 18Gy < 50% | 23.52 ± 1.22 | 24.58 ± 3.16 | 24.21 ± 2.84 | 0.416 | 0.393 | 0.668 | 0.892 | |
| Bladder | V 37Gy < 10cc | 4.23 ± 0.62 | 4.50 ± 0.54 | 4.36 ± 0.44 | 0.286 | 0.254 | 0.706 | 0.703 |
| V 36.25Gy < 10% | 3.80 ± 0.29 | 3.91 ± 0.41 | 3.83 ± 0.32 | 0.286 | 0.254 | 0.706 | 0.703 | |
| V 32.60Gy < 15% | 5.65 ± 0.25 | 5.64 ± 0.43 | 5.63 ± 0.34 | 0.989 | 0.997 | 0.988 | 0.997 | |
| V 29Gy < 25% | 7.20 ± 0.27 | 7.15 ± 0.46 | 7.17 ± 0.39 | 0.918 | 0.911 | 0.968 | 0.984 | |
| V 18Gy < 55% | 12.65 ± 0.37 | 12.52 ± 0.58 | 12.59 ± 0.53 | 0.701 | 0.677 | 0.91 | 0.903 | |
| Femoral head right | V 18Gy < 4 cc | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.314 | 0.821 | 0.625 | 0.287 |
| Femoral head left | V 18Gy < 4 cc | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.03 | 0.166 | 0.999 | 0.218 | 0.237 |
| Skin | Dmax < 15Gy | 11.14 ± 0.60 | 11.02 ± 0.64 | 1.47 ± 0.90 | 0.147 | 0.985 | 0.342 | 0.141 |
| Monitor units | MU | 2319 (1988-2597) | 2315 (2070-2486) | 2382 (2040-3145) | < 0.01 | < 0.01 | < 0.01 | < 0.01 |
The bold numbers indicate a statistically significant difference between plans (ANOVA test).